Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06108024 · ClinicalTrials.gov registry record · Phase 2
A Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratosis
A Phase 2 study of Seborrheic Keratosis, sponsored by DermBiont.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 4
- Study locations
NCT06108024: Recruiting Phase 2 study of Seborrheic Keratosis, sponsored by DermBiont.
NCT06108024 is a Phase 2 study of Seborrheic Keratosis that is actively recruiting participants, run by DermBiont. The registered enrollment target is 60 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower). The trial reports 4 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06108024, a Phase 2 study of Seborrheic Keratosis, is actively recruiting participants, sponsored by DermBiont.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 4
- Study locations
Study Summary
The objective of the trial is to evaluate the safety and efficacy of SM-020 gel 1.0% in subjects with Seborrheic Keratosis (SK) compared to vehicle gel. It is a randomized, double-blind, vehicle-controlled trial. Approximately 60 subjects will be enrolled. Subjects will apply their assigned investigational product twice daily for 4 consecutive weeks. Subjects will be followed for 12-weeks post final application for a total of approximately 16-weeks of required participation in the study.
Conditions Studied
Interventions
- DRUG SM-020 gel 1.0%
- DRUG Vehicle gel
Study Locations (4)
Oregon
- Oregon Medical Research Center - Portland
- Oregon Dermatology and Research Center - Portland
Florida
- Driven Research LLC - Coral Gables
Minnesota
- Minnesota Clinical Study Center - New Brighton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-11-06 |
| Est. Completion | 2024-10-15 |
| Phase | Phase 2 |
What NCT06108024 shows while recruiting
NCT06108024 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (55% lower).
The record links to 1 condition, with Seborrheic Keratosis appearing as the primary indexed condition, and to 2 interventions - of which SM-020 gel 1.0% is the first listed.
NCT06108024 reports a single indexed study location in Oregon, Florida, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06108024 about?
NCT06108024 is a clinical study titled "A Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratosis". The objective of the trial is to evaluate the safety and efficacy of SM-020 gel 1.0% in subjects with Seborrheic Keratosis (SK) compared to vehicle gel. It is a randomized, double-blind, vehicle-controlled trial. Approximately 60 subjects will be enrolled. Subjects will apply their assigned investig...
What is the current status of trial NCT06108024?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2023-11-06. Estimated completion is 2024-10-15.
What conditions does trial NCT06108024 study?
This clinical trial studies the following conditions: Seborrheic Keratosis.
What interventions are being tested in trial NCT06108024?
The interventions under investigation include: SM-020 gel 1.0% (DRUG), Vehicle gel (DRUG).
Who is sponsoring clinical trial NCT06108024?
This trial is sponsored by DermBiont, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06108024 being conducted?
This trial has 4 study locations across Florida, Minnesota, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Seborrheic Keratosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06108024's enrollment target sits among peer trials
60 1027th of 2000 higher than 869 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI